4-(aminomethyl)-N-ethylbenzamide | 777055-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(aminomethyl)-N-ethylbenzamide
• 英文别名: N-Ethyl 4-(aminomethyl)benzamide
• CAS: 777055-55-7
• 化学式: C₁₀H₁₄N₂O
• mdl: MFCD09050879
• 分子量: 178.234
• InChiKey: YUCCNGHVNHMOBD-UHFFFAOYSA-N

物化性质

• 沸点：
  361.2±25.0 °C(Predicted)
• 密度：
  1.071±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(aminomethyl)-N-ethylbenzamide 、 9-[5-S-(2-acetamidoethyl)-2,3-di-O-acetyl-5-thio-β-D-ribofuranosyl]-6-fluoropurine 在 三乙胺 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Improved Syntheses of 5′-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), Analogues, and Fluorescent Probe Conjugates: Analysis of Cell-Surface Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels for Prediction of the Antitumor Efficacy of Gemcitabine

  摘要：

  5'-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), 5'-S-(2-acetamidoethyl)-6-N-[(4-substituted)benzyl]-5'-thioadenosine analogues, 5'-S-[2-(6-aminohexanamido)lethyl-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAHENTA), and related compounds were synthesized by S(N)Ar displacement of fluoride from 6-fluoropurine intermediates with 4-(substituted)benzylamines. Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Transporter binding effects were studied and the ability of the probes to predict the potential antitumor efficacy of 2'-deoxy-2',2'-difluorocylidine (gemcitabine) was demonstrated.

  DOI：

  10.1021/jm100432w
• 作为产物：
  描述：

  N-ethyl-4-[(trifluoroacetamido)methyl]benzamide 在 ammonium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 8.0h， 生成 4-(aminomethyl)-N-ethylbenzamide
  参考文献：
  名称：

  Improved Syntheses of 5′-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), Analogues, and Fluorescent Probe Conjugates: Analysis of Cell-Surface Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels for Prediction of the Antitumor Efficacy of Gemcitabine

  摘要：

  5'-S-(2-Aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), 5'-S-(2-acetamidoethyl)-6-N-[(4-substituted)benzyl]-5'-thioadenosine analogues, 5'-S-[2-(6-aminohexanamido)lethyl-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAHENTA), and related compounds were synthesized by S(N)Ar displacement of fluoride from 6-fluoropurine intermediates with 4-(substituted)benzylamines. Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Transporter binding effects were studied and the ability of the probes to predict the potential antitumor efficacy of 2'-deoxy-2',2'-difluorocylidine (gemcitabine) was demonstrated.

  DOI：

  10.1021/jm100432w

文献信息

• [EN] NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE CYCLOSPORINE ET LEURS UTILISATIONS
  申请人：S&T GLOBAL INC

  公开号：WO2017200984A1

  公开（公告）日：2017-11-23

  A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

  公开了化合物的公式（I）：（I）或其药学上可接受的盐，其中符号如规范中定义。还描述了包含相同化合物的药物组合物，以及使用该药物组合物治疗或预防病毒感染、炎症、干眼症、中枢神经障碍、心血管疾病、癌症、肥胖症、糖尿病、肌肉萎缩症、肺部和肝脏疾病、肾脏疾病和脱发的方法。
• OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM
  申请人：GIFU UNIVERSITY

  公开号：US20180094017A1

  公开（公告）日：2018-04-05

  The oligonucleotide derivative of the present invention is represented by Formula (1). This derivative is considered to be introduced into cells by binding of its amino sugar chain moiety to a ligand on cell surfaces, and have selective drug delivery function. The oligonucleotide derivative can be easily synthesized and introduced into cells without using a lipofection reagent. wherein—A and B are independently modified or unmodified oligonucleotides whose total chain length is 3 or more, and A and B do not contain hydroxyl groups at 3′ and 5′ ends of the oligonucleotide; S represents a sugar substituent, a peptide chain, or a tocopherol-binding group; and an alkyl group may be bound instead of hydrogen bound to a benzene ring.

  本发明的寡核苷酸衍生物由式（1）表示。该衍生物被认为通过其氨基糖链部分与细胞表面的配体结合而被引入细胞，并具有选择性药物传递功能。该寡核苷酸衍生物可以在不使用脂质体载体的情况下轻松合成并引入细胞。其中，A和B分别是经修饰或未经修饰的寡核苷酸，其总链长为3或更长，且A和B不含有寡核苷酸的3′和5′末端的羟基；S代表糖取代基、肽链或生育酚结合基；和烷基基团可以与苯环上的氢结合而不是氢结合。
• BIGUANIDE COMPOUNDS AND USE THEREOF
  申请人：HANALL BIOPHARMA CO., LTD.

  公开号：US20150126518A1

  公开（公告）日：2015-05-07

  The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.

  本发明涉及双胍类化合物及其使用，更具体地涉及表现出对抑制癌细胞增殖、抑制癌转移和复发具有优异效果的双胍衍生物，以及制备该化合物的方法、含有该化合物作为活性成分的药物组合物，以及包括向需要的受试者施用所述组合物的有效量的步骤的癌症预防或治疗方法。
• New Mild and Simple Approach to Isothiocyanates: A Class of Potent Anticancer Agents
  作者：Bingling Luo、Jiankang Wang、Xiaobing Li、Wenhua Lu、Jing Yang、Yumin Hu、Peng Huang、Shijun Wen

  DOI：10.3390/molecules22060773

  日期：——

  In our current work, acetyl chloride-mediated synthesis of phenethyl isothiocyanate (PEITC) derivatives proves to be convenient and provides the expected products at good to excellent yields. Biological evaluation and structure-activity relationship analysis found that the novel compound 7 showed the best anticancer activity against human cancer cell line Panc1 and HGC27 compared with PEITC. Compounds

  在我们目前的工作中，乙酰氯介导的异硫氰酸苯乙酯 (PEITC) 衍生物合成被证明是方便的，并以良好的收率提供预期的产品。生物学评价和构效关系分析发现，与PEITC相比，新型化合物7对人癌细胞系Panc1和HGC27的抗癌活性最好。化合物 6 和 7 在胰腺癌细胞中诱导更多的细胞凋亡，但在非癌细胞中的毒性较小。进一步的生物学研究表明，7 种细胞内活性氧 (ROS) 和耗尽型谷胱甘肽 (GSH) 显着增加，导致氧化应激杀死癌细胞。
• Biguanide compounds and use thereof
  申请人：IMMUNOMET THERAPEUTICS INC.

  公开号：US10221190B2

  公开（公告）日：2019-03-05

  The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.

  本发明涉及双胍类化合物及其用途，更具体地说，涉及在抑制癌细胞增殖、抑制癌症转移和复发方面具有卓越效果的双胍类衍生物、制备方法、含有双胍类衍生物作为活性成分的药物组合物，以及预防或治疗癌症的方法，该方法包括向有需要的受试者施用有效量的组合物的步骤。